

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



ОН

(±)-Ketoprofen-d₂

Item No. 28148

CAS Registry No.: 159490-55-8

Formal Name: 3-benzoyl-α-(methyl-d₃)-benzeneacetic acid

Synonyms: (R,S)-Ketoprofen-d₃,

2-(3-benzoylphenyl)Propionic Acid-d₃

MF: $C_{16}H_{11}D_3O_3$ 257.3 FW:


Chemical Purity: ≥98% ((±)-Ketoprofen)

Deuterium

Incorporation:

Supplied as: -20°C Storage: Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

(±)-Ketoprofen-d₂ is intended for use as an internal standard for the quantification of (±)-ketoprofen (Item No. 10006661) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

 (\pm) -Ketoprofen- d_3 is supplied as a solid. A stock solution may be made by dissolving the (\pm) -ketoprofen- d_3 in the solvent of choice. (±)-Ketoprofen-d₃ is soluble in organic solvents such as methanol and DMSO, which should be purged with an inert gas.

Description

(±)-Ketoprofen is a non-selective COX inhibitor and non-steroidal anti-inflammatory drug (NSAID).¹ It inhibits human recombinant COX-1 and COX-2 with IC $_{50}$ values of 0.5 and 2.33 μ M, respectively. In vivo, (±)-ketoprofen reduces carrageenan-induced paw edema and increases latency to paw withdrawal in the hot plate test in rats when administered using a sustained-release implant.² Formulations containing (±)-ketoprofen have been used to treat pain and inflammation in osteoarthritis.

References

- 1. Barnett, J., Chow, J., Ives, D., et al. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys. Acta. 1209(1), 130-139 (1994).
- 2. Zhang, J., Xu, X., Zhu, L., et al. Preparation and pre-clinical characterization of sustained release ketoprofen implants for the management of pain and inflammation in osteoarthritis. Trop. J. Pharm. Res. **17(4)**, 577-582 (2018).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 09/12/2019

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM